Unicycive Therapeutics Inc (UNCY)

$5.05 +0.03 (0.60%)
Market Cap 137.51M
Revenue (ttm) 0.00
Net Income (ttm) -26.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 857,100
Avg Vol 1,676,052
Day's Range N/A - N/A
Shares Out 27.39M
Stochastic %K 13%
Beta 1.79
Analysts Strong Sell
Price Target $34.89

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
1975 West El Camino Real, Suite 204, Mountain View, United States
erictwin1
erictwin1 Jul. 16 at 7:51 PM
$UNCY Looks like the consensus in this room is uncy sucks.
1 · Reply
zawojak
zawojak Jul. 16 at 1:11 PM
$CCCC $NUVB $UNCY $AQST $NLST Who still believes we are NOT in a BEAR market? 😬😬😬📉📉📉🔻🔻🔻
1 · Reply
1nvestorGadget
1nvestorGadget Jul. 15 at 7:49 PM
$UNCY sub-$5.00 the new reality eminent. You should thank me not talk smack. I’d be saving you money if you listened.
4 · Reply
erictwin1
erictwin1 Jul. 15 at 5:11 PM
$UNCY manor buying time at under 5
0 · Reply
BLtheKid
BLtheKid Jul. 15 at 4:43 PM
$UNCY 16 five-minute bars in a row with a flat or lower high, I wonder what the odds are on something like that? on almost no volume, I should add.
0 · Reply
erictwin1
erictwin1 Jul. 14 at 12:49 PM
$UNCY Maxim just gave a buy rating with a 30 dollar strike price, buy now while there cheap💰💰💰
2 · Reply
toni1965
toni1965 Jul. 14 at 8:00 AM
$UNCY Market Maker Manipulation Galore
0 · Reply
ccledez
ccledez Jul. 13 at 4:06 PM
$GRCE according to Gemini as far as order of catalysts It's grce $UNCY And last $CING Probably a good idea to have a little of all 3
0 · Reply
erictwin1
erictwin1 Jul. 13 at 3:40 PM
$UNCY just bought a ton more shares at 5.06!!! this is a steal of a price. Get in now folks
2 · Reply
BLtheKid
BLtheKid Jul. 13 at 2:20 PM
$UNCY I am coming down with a case of algo and MM fatigue, day after day with the same nonsense, year after year after year
0 · Reply
Latest News on UNCY
Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

2026-07-01T13:45:11.000Z - 15 days ago

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

2026-07-01T12:50:20.000Z - 15 days ago

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Jun 30, 2026, 12:51 PM EDT - 16 days ago

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

2026-06-30T16:35:10.000Z - 16 days ago

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

2026-06-30T14:50:20.000Z - 16 days ago

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

2026-06-30T11:25:41.000Z - 17 days ago

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Jun 30, 2026, 7:05 AM EDT - 17 days ago

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Unicycive Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 24 days ago

Unicycive Therapeutics Proxy statement: Proxy filing

Unicycive Therapeutics files $150M mixed securities shelf

2026-06-05T20:20:10.000Z - 5 weeks ago

Unicycive Therapeutics files $150M mixed securities shelf

Unicycive Therapeutics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 5 weeks ago

Unicycive Therapeutics Registration statement: Registration filing

Unicycive Therapeutics Slides: Corporate presentation

Jun 4, 2026, 7:00 AM EDT - 6 weeks ago

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

2026-06-02T13:07:41.000Z - 6 weeks ago

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 6 weeks ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics management to meet virtually with Piper Sandler

2026-05-28T15:05:39.000Z - 7 weeks ago

Unicycive Therapeutics management to meet virtually with Piper Sandler

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

2026-05-13T11:14:54.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

Unicycive Therapeutics Slides: Company presentation

May 13, 2026, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics Slides: Company presentation

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

2026-05-12T11:51:45.000Z - 2 months ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:05 AM EDT - 2 months ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics initiated with a Buy at B. Riley

2026-05-01T14:07:09.000Z - 2 months ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 3:45 PM EDT - 3 months ago

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 3 months ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-06T11:30:08.000Z - 3 months ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

2026-04-02T10:59:29.000Z - 3 months ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 7:05 AM EDT - 3 months ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Unicycive Therapeutics management to meet with Piper Sandler

2026-02-20T14:22:23.000Z - 5 months ago

Unicycive Therapeutics management to meet with Piper Sandler

Unicycive Therapeutics initiated with a Buy at WestPark Capital

2026-02-19T12:57:38.000Z - 5 months ago

Unicycive Therapeutics initiated with a Buy at WestPark Capital

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 5 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 5 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 6 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

2026-01-29T12:15:28.000Z - 6 months ago

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 6 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

2025-12-29T12:10:32.000Z - 7 months ago

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 7 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 8 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 8 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 8 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 9 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 9 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 11 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 18, 2025, 7:05 AM EDT - 11 months ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

erictwin1
erictwin1 Jul. 16 at 7:51 PM
$UNCY Looks like the consensus in this room is uncy sucks.
1 · Reply
zawojak
zawojak Jul. 16 at 1:11 PM
$CCCC $NUVB $UNCY $AQST $NLST Who still believes we are NOT in a BEAR market? 😬😬😬📉📉📉🔻🔻🔻
1 · Reply
1nvestorGadget
1nvestorGadget Jul. 15 at 7:49 PM
$UNCY sub-$5.00 the new reality eminent. You should thank me not talk smack. I’d be saving you money if you listened.
4 · Reply
erictwin1
erictwin1 Jul. 15 at 5:11 PM
$UNCY manor buying time at under 5
0 · Reply
BLtheKid
BLtheKid Jul. 15 at 4:43 PM
$UNCY 16 five-minute bars in a row with a flat or lower high, I wonder what the odds are on something like that? on almost no volume, I should add.
0 · Reply
erictwin1
erictwin1 Jul. 14 at 12:49 PM
$UNCY Maxim just gave a buy rating with a 30 dollar strike price, buy now while there cheap💰💰💰
2 · Reply
toni1965
toni1965 Jul. 14 at 8:00 AM
$UNCY Market Maker Manipulation Galore
0 · Reply
ccledez
ccledez Jul. 13 at 4:06 PM
$GRCE according to Gemini as far as order of catalysts It's grce $UNCY And last $CING Probably a good idea to have a little of all 3
0 · Reply
erictwin1
erictwin1 Jul. 13 at 3:40 PM
$UNCY just bought a ton more shares at 5.06!!! this is a steal of a price. Get in now folks
2 · Reply
BLtheKid
BLtheKid Jul. 13 at 2:20 PM
$UNCY I am coming down with a case of algo and MM fatigue, day after day with the same nonsense, year after year after year
0 · Reply
elmono
elmono Jul. 13 at 2:01 PM
$UNCY c*ck s*cking algo rithmic stealing
0 · Reply
the_Bull1
the_Bull1 Jul. 13 at 1:48 PM
$UNCY No one mentions the EMA inspection of the same manufacturer Shilpa Medicare after the first CRL at the end of 2025 (after which they made a resubmission) and that it passed successfully. The EMA and FDA criteria are the same.
1 · Reply
Legendary_Scoober
Legendary_Scoober Jul. 13 at 1:16 PM
$UNCY I just need this turd to rise $1.20 so I can get my money back.
0 · Reply
900fix
900fix Jul. 12 at 7:24 PM
$UNCY Is Gupta setting up this up for CRL #3? Looks like it. What an idiot. Back to the 7-11 for all of them.
2 · Reply
1nvestorGadget
1nvestorGadget Jul. 10 at 7:58 PM
$UNCY https://x.com/1nvestorgadget/status/2075665046009708631?s=46&t=tCeRobHWSkSVGMhPDlFb3A
2 · Reply
BioRich
BioRich Jul. 10 at 7:55 PM
$UNCY Leads our "Five to Thrive" going into the weekend: 1) $UNCY 2) $GUTS 3) $CAPR 4) $OTLK 5) $ABCL Each is poised for massive recovery (or continued run/growth). Risk/Reward plays that I'm very excited about. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's makes some (more) money. Cheers!
2 · Reply
SpaceRocketX
SpaceRocketX Jul. 10 at 4:44 PM
$UNCY
0 · Reply
BLtheKid
BLtheKid Jul. 10 at 1:42 PM
$UNCY MM goofballs working it hard early!
0 · Reply
killbilltrader
killbilltrader Jul. 10 at 1:26 PM
$VERA $UNCY gets a CRL and goes up, we receive an FDA approval in a 20B market and stay in the red ever since we received a greenlight🤦‍♂️🤦‍♂️
1 · Reply
Logmart939
Logmart939 Jul. 10 at 1:07 AM
$UNCY why is it going down so much after hours
3 · Reply
erictwin1
erictwin1 Jul. 9 at 6:58 PM
$UNCY buying always picks up last hour of the trading day, so everyone start buying!!!!!
1 · Reply
PolyhedronPivot
PolyhedronPivot Jul. 9 at 6:36 PM
$UNCY amended 13G out: Millennium reporting 271,456 shares, 1.0%. Integrated Core Strategies separately at 205,529 shares, 0.8%. Not a control stake. Not a whale-sized flex. Just fresh positioning on the tape — small, but worth noting if you’re tracking who’s still hanging around this name.
1 · Reply